Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
200 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-10-26
Study Completion Date
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Assessment of Gastric Bypass combined with Vertical Sleeve Gastrectomy as primary treatment for patients with severe clinical obesity.
Average percentage of total weight loss and percentage excess weight loss will be computed at 6 months, one year and then annually. Comorbid conditions, quality of life measures, appetite and satiety measures and adverse events will be tracked.
Average percentage of total weight loss and percentage excess weight loss will be computed at 6 months, one year and then annually. Comorbid conditions, quality of life measures, appetite and satiety measures and adverse events will be tracked.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery
NCT03530566
Obesity, Morbid
Bariatric Surgery
Comorbidity
UNKNOWN
Outcomes of Bariatric Surgery/UMMMC Bariatric Surgery Registry
NCT01153308
Morbid Obesity
COMPLETED
Laparoscopic Gastric Plication Operation for Patients With Severe or Morbid Obesity
NCT01207609
Morbid Obesity
COMPLETED
NA
Acceptability and Feasibility of a Preoperative Very Low Calorie Diet Intervention on Surgical Weight Loss Outcomes (SAFETY)
NCT06183034
Obesity
NOT_YET_RECRUITING
NA
Stomach Intestinal Pylorus-Sparing Bariatric Surgery
NCT05094830
Obesity
TERMINATED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND
Metabolic Disease and Obesity
Obesity is one of the most common chronic diseases in America and is strongly associated with additional metabolic disorders, in particular hypertension, dyslipidemia and insulin resistance. The combination of obesity with this cluster of metabolic disorders increases risk for cardiovascular disease and is widely recognized by the term Metabolic Syndrome.
According to the Centers for Disease Control, in 2017-2018 the "prevalence of severe obesity among U.S. adults was 9.2%", the "age-adjusted prevalence of obesity in adults was 42.4%", and the prevalence of metabolic syndrome (MS) in the obese population is higher than 60%. The economic impact of metabolic syndrome is significant, with risk factors for MS shown to increase a person's annual healthcare costs by more than $2000.
Efforts to treat obesity and obesity-associated metabolic disease currently include medical management and surgical intervention. Success rates with surgical interventions exceed those of medical management but are dependent on patients making permanent changes in eating behaviors.
Commonly accepted surgical procedures have several mechanisms of action. These include decreased stomach volume restricting a patient's ability to eat, intestinal bypass resulting in significant malabsorption, and alterations in hormonal control of appetite and satiety. Standardized surgical procedures include Vertical Sleeve Gastrectomy (VSG), Roux-en-Y Gastric Bypass (GBP), Laparoscopic Gastric Banding (LB) and Biliopancreatic Diversion with Duodenal Switch (DS). Of these, VSG and GBP are the most commonly performed.
VSG and GBP have been shown to result in similar weight loss, however, both procedures have a significant long-term failure rate.
Key symptomatic differences between VSG and GBP
During the initial 6-12 months after surgery, both VSG and GBP patients typically report a marked decrease in appetite as well as a significant restriction in volume of food that can be eaten before "feeling full." This period of decreased appetite and early satiety is commonly referred to as the "honeymoon period." After this honeymoon period, every patient's weight loss success becomes progressively more dependent on changes made in their eating habits.
As would be expected with anatomically distinct procedures, patient symptoms begin to significantly differ over time. Patients that have undergone GBP, resulting in a gastric pouch that is less than 30cc report a more sustained feeling of restriction in the volume of food that can be eaten at a single meal compared to patients that have undergone VSG with a 100-150cc residual stomach. GBP patients also report a more persistent feeling of early satiety than do patients after VSG. In contrast, patients that have undergone VSG, with most of the Ghrelin-producing region of their stomach removed, report a more persistent decrease in appetite compared to patients after GBP, where the production of Ghrelin appears to rebound.
Key hormonal differences between VSG and GBP
VSG results in substantial and permanent decrease in the orexigenic hormone Ghrelin. After GBP, rebound of Ghrelin is shown to occur within 6 to 12 months after surgery.
GBP causes a significantly greater increase in postprandial GLP-1 and Peptide YY, possibly contributing to earlier satiety and improved glycemic control.
Key differences in side effects between VSG and GBP
A common side effect of VSG is GERD. When symptoms are severe, conversion to GBP provides relief.
Dumping syndrome, a side effect of GBP, is often described as an effective negative feedback mechanism, helping to minimize ingestion of high glycemic index foods. Dumping is not typically associated with VSG.
Considering these differences, it is reasonable to question whether a single-stage procedure that combines the anatomic changes of both the GBP and VSG would result in;
1. Improved weight loss
2. An improved quality of life
3. Better glycemic control
PROPOSED STUDY
Surgical Intervention
The S.L.I.M.M.S. Procedure, for Surgically Limit Intake and Manage Metabolic Syndrome, is a single-stage operation combining Roux-en-Y Gastric Bypass with Partial Gastrectomy. The procedure specifications are listed below,
1. A 20 cc gastric pouch
2. A 10 mm diameter gastro-jejunal stoma
3. A 40 cm biliopancreatic limb (measured from the Ligament of Treitz)
4. A 150 cm roux limb
5. Resection of the remaining fundus and body of the stomach, maintaining the majority of the gastric antrum
6. Oversewing the gastric staple lines and buttressing with omentum
Most new procedures focus on variations of intestinal reconstruction, or involve implantation of artificial devices. The proposed procedure does not require implantation of an artificial device, nor a new method of intestinal reconstruction. It simply combines the two most common bariatric procedures in the world with the hope of providing cumulative benefits without increased risk.
Key Technical and Anatomic Precedents
1. When VSG results in severe and recalcitrant GERD the standard treatment is conversion to GBP. The final anatomic result is a patient with a gastric bypass and the majority of the gastric fundus and body removed. This is similar to the final anatomy of the procedure proposed in this study, however, the S.L.I.M.M.S. procedure will be done as a single operation.
2. In several centers, resectional gastric bypass, involving a standard gastric bypass combined with a subtotal or total gastrectomy, is performed routinely \[24-28\]. Published reports from these centers do not demonstrate increased complications.
Significance of this Study
Currently accepted surgical procedures all have significant long-term failure rates or frequently result in substantial malnutrition. Multiple new and novel surgical procedures are currently being tried that focus either on simple restriction or on increasing malabsorption. These new procedures are not designed with the intention of providing increased, permanent support for the patient's behavioral changes which are so critical in the long-term success of all bariatric surgery. The S.L.I.M.M.S. procedure is designed with the primary goal of a more sustained appetite suppression and increased early satiety.
Aims of This Study
The specific aim of the study is to assess the safety and efficacy of the S.L.I.M.M.S. Procedure as a stand-alone, single-stage bariatric operation.
METHODS
Trial Protocol
1. Patient Recruitment
a. Recruitment into the study will be achieved by a physician awareness campaign using direct mail. An Internet awareness campaign will target potential patients. Announcements will include description of planned procedure, aim of study and experimental nature of the S.L.I.M.M.S. Procedure.
2. Patient Education
a. Patient Education consisting of i. Detailed Consultation ii. Patient Education Packet iii. Written Examination iv. Education on pre- and post-operative dietary protocols v. Mandatory Dietary Rebuild counselling program vi. Permanent Surgical Weight Loss book provided vii. DietaryRebuild™ book provided viii. Exercise Instructions ix. Nutrition Supplementation Instructions
3. Patient Enrolment
a. Enrolment into the study will be proceeded by patient education including a detailed discussion of the nature of this clinical trial. A detailed consent will also be provided.
4. Pre-trial Assessment
1. Initial clinical assessment will include a detailed dietary history and a review for co-morbidities of obesity.
2. Assessment of nutrition knowledge and quality of life will be obtained using the General Nutrition Knowledge Questionnaire, the Bariatric Quality of Life Index and the SF-36/Rand.
3. Clinical assessment will include various weight parameters and measurement of serum glucose, hemoglobin A1c, lipids, vitamin levels, iron, ferritin, RBC folate, complete blood count, comprehensive metabolic profile, and abdominal ultrasound.
5. Surgery: S.L.I.M.M.S. Procedure
6. Patient Support
1. In-clinic follow up
2. Support groups offered
3. Telephone-based group counselling sessions
7. Post-operative Assessment
1. Weight Parameters measured at 6 months, 12 months and annually
2. Laboratory assessment will include serum glucose, hemoglobin A1c, lipids, vitamin levels, iron, ferritin, RBC folate, complete blood count, comprehensive metabolic profile and lipid profile at 6 months, 12 months and annually thereafter
3. Quality of life measure at 1, 12 and 24 months; Bariatric Quality of Life Index and SF-36/Rand
Metabolic Disease and Obesity
Obesity is one of the most common chronic diseases in America and is strongly associated with additional metabolic disorders, in particular hypertension, dyslipidemia and insulin resistance. The combination of obesity with this cluster of metabolic disorders increases risk for cardiovascular disease and is widely recognized by the term Metabolic Syndrome.
According to the Centers for Disease Control, in 2017-2018 the "prevalence of severe obesity among U.S. adults was 9.2%", the "age-adjusted prevalence of obesity in adults was 42.4%", and the prevalence of metabolic syndrome (MS) in the obese population is higher than 60%. The economic impact of metabolic syndrome is significant, with risk factors for MS shown to increase a person's annual healthcare costs by more than $2000.
Efforts to treat obesity and obesity-associated metabolic disease currently include medical management and surgical intervention. Success rates with surgical interventions exceed those of medical management but are dependent on patients making permanent changes in eating behaviors.
Commonly accepted surgical procedures have several mechanisms of action. These include decreased stomach volume restricting a patient's ability to eat, intestinal bypass resulting in significant malabsorption, and alterations in hormonal control of appetite and satiety. Standardized surgical procedures include Vertical Sleeve Gastrectomy (VSG), Roux-en-Y Gastric Bypass (GBP), Laparoscopic Gastric Banding (LB) and Biliopancreatic Diversion with Duodenal Switch (DS). Of these, VSG and GBP are the most commonly performed.
VSG and GBP have been shown to result in similar weight loss, however, both procedures have a significant long-term failure rate.
Key symptomatic differences between VSG and GBP
During the initial 6-12 months after surgery, both VSG and GBP patients typically report a marked decrease in appetite as well as a significant restriction in volume of food that can be eaten before "feeling full." This period of decreased appetite and early satiety is commonly referred to as the "honeymoon period." After this honeymoon period, every patient's weight loss success becomes progressively more dependent on changes made in their eating habits.
As would be expected with anatomically distinct procedures, patient symptoms begin to significantly differ over time. Patients that have undergone GBP, resulting in a gastric pouch that is less than 30cc report a more sustained feeling of restriction in the volume of food that can be eaten at a single meal compared to patients that have undergone VSG with a 100-150cc residual stomach. GBP patients also report a more persistent feeling of early satiety than do patients after VSG. In contrast, patients that have undergone VSG, with most of the Ghrelin-producing region of their stomach removed, report a more persistent decrease in appetite compared to patients after GBP, where the production of Ghrelin appears to rebound.
Key hormonal differences between VSG and GBP
VSG results in substantial and permanent decrease in the orexigenic hormone Ghrelin. After GBP, rebound of Ghrelin is shown to occur within 6 to 12 months after surgery.
GBP causes a significantly greater increase in postprandial GLP-1 and Peptide YY, possibly contributing to earlier satiety and improved glycemic control.
Key differences in side effects between VSG and GBP
A common side effect of VSG is GERD. When symptoms are severe, conversion to GBP provides relief.
Dumping syndrome, a side effect of GBP, is often described as an effective negative feedback mechanism, helping to minimize ingestion of high glycemic index foods. Dumping is not typically associated with VSG.
Considering these differences, it is reasonable to question whether a single-stage procedure that combines the anatomic changes of both the GBP and VSG would result in;
1. Improved weight loss
2. An improved quality of life
3. Better glycemic control
PROPOSED STUDY
Surgical Intervention
The S.L.I.M.M.S. Procedure, for Surgically Limit Intake and Manage Metabolic Syndrome, is a single-stage operation combining Roux-en-Y Gastric Bypass with Partial Gastrectomy. The procedure specifications are listed below,
1. A 20 cc gastric pouch
2. A 10 mm diameter gastro-jejunal stoma
3. A 40 cm biliopancreatic limb (measured from the Ligament of Treitz)
4. A 150 cm roux limb
5. Resection of the remaining fundus and body of the stomach, maintaining the majority of the gastric antrum
6. Oversewing the gastric staple lines and buttressing with omentum
Most new procedures focus on variations of intestinal reconstruction, or involve implantation of artificial devices. The proposed procedure does not require implantation of an artificial device, nor a new method of intestinal reconstruction. It simply combines the two most common bariatric procedures in the world with the hope of providing cumulative benefits without increased risk.
Key Technical and Anatomic Precedents
1. When VSG results in severe and recalcitrant GERD the standard treatment is conversion to GBP. The final anatomic result is a patient with a gastric bypass and the majority of the gastric fundus and body removed. This is similar to the final anatomy of the procedure proposed in this study, however, the S.L.I.M.M.S. procedure will be done as a single operation.
2. In several centers, resectional gastric bypass, involving a standard gastric bypass combined with a subtotal or total gastrectomy, is performed routinely \[24-28\]. Published reports from these centers do not demonstrate increased complications.
Significance of this Study
Currently accepted surgical procedures all have significant long-term failure rates or frequently result in substantial malnutrition. Multiple new and novel surgical procedures are currently being tried that focus either on simple restriction or on increasing malabsorption. These new procedures are not designed with the intention of providing increased, permanent support for the patient's behavioral changes which are so critical in the long-term success of all bariatric surgery. The S.L.I.M.M.S. procedure is designed with the primary goal of a more sustained appetite suppression and increased early satiety.
Aims of This Study
The specific aim of the study is to assess the safety and efficacy of the S.L.I.M.M.S. Procedure as a stand-alone, single-stage bariatric operation.
METHODS
Trial Protocol
1. Patient Recruitment
a. Recruitment into the study will be achieved by a physician awareness campaign using direct mail. An Internet awareness campaign will target potential patients. Announcements will include description of planned procedure, aim of study and experimental nature of the S.L.I.M.M.S. Procedure.
2. Patient Education
a. Patient Education consisting of i. Detailed Consultation ii. Patient Education Packet iii. Written Examination iv. Education on pre- and post-operative dietary protocols v. Mandatory Dietary Rebuild counselling program vi. Permanent Surgical Weight Loss book provided vii. DietaryRebuild™ book provided viii. Exercise Instructions ix. Nutrition Supplementation Instructions
3. Patient Enrolment
a. Enrolment into the study will be proceeded by patient education including a detailed discussion of the nature of this clinical trial. A detailed consent will also be provided.
4. Pre-trial Assessment
1. Initial clinical assessment will include a detailed dietary history and a review for co-morbidities of obesity.
2. Assessment of nutrition knowledge and quality of life will be obtained using the General Nutrition Knowledge Questionnaire, the Bariatric Quality of Life Index and the SF-36/Rand.
3. Clinical assessment will include various weight parameters and measurement of serum glucose, hemoglobin A1c, lipids, vitamin levels, iron, ferritin, RBC folate, complete blood count, comprehensive metabolic profile, and abdominal ultrasound.
5. Surgery: S.L.I.M.M.S. Procedure
6. Patient Support
1. In-clinic follow up
2. Support groups offered
3. Telephone-based group counselling sessions
7. Post-operative Assessment
1. Weight Parameters measured at 6 months, 12 months and annually
2. Laboratory assessment will include serum glucose, hemoglobin A1c, lipids, vitamin levels, iron, ferritin, RBC folate, complete blood count, comprehensive metabolic profile and lipid profile at 6 months, 12 months and annually thereafter
3. Quality of life measure at 1, 12 and 24 months; Bariatric Quality of Life Index and SF-36/Rand
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Morbid Obesity
Metabolic Syndrome
Type2 Diabetes
Insulin Resistance
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Prospective Single Group Clinical Trial
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
S.L.I.M.M.S. Procedure
Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure
Group Type
EXPERIMENTAL
S.L.I.M.M.S. Procedure
Intervention Type
PROCEDURE
Combined Gastric Bypass with Vertical Sleeve Gastrectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S.L.I.M.M.S. Procedure
Combined Gastric Bypass with Vertical Sleeve Gastrectomy
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Bariatric Surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be between 18 and 65 years of age
2. Have a body mass index of equal to or above 35 kgs per m2
3. Have identifiable obesity-related comorbidity; medical, physical or psycho-social
4. A history of attempts at weight reduction within the past five-year period
5. Ability to understand the non-surgical and surgical options for weight loss
6. Understand the behavioral changes needed to maximize surgical weight loss success
7. Agree to comply with recommended follow-up clinical assessments
8. Agree to comply with lifelong nutritional supplementation
2. Have a body mass index of equal to or above 35 kgs per m2
3. Have identifiable obesity-related comorbidity; medical, physical or psycho-social
4. A history of attempts at weight reduction within the past five-year period
5. Ability to understand the non-surgical and surgical options for weight loss
6. Understand the behavioral changes needed to maximize surgical weight loss success
7. Agree to comply with recommended follow-up clinical assessments
8. Agree to comply with lifelong nutritional supplementation
Exclusion Criteria
1. Lack of ability to understand weight loss options and requirements for long-term success with surgery
2. Inability to understand and accept the risks and potential benefits
3. Inability to understand and agree to the compliance requirements of the study
4. Prior gastric surgery including all forms of bariatric surgical or endoscopic procedures
5. A history of previous abdominal surgery which precludes gastric bypass
6. Medical contra-indications to bariatric surgery
7. Dementia, active psychosis, unstable psychiatric disease
8. Concurrent experimental drug use
9. Pregnancy or intending to conceive within 12 months or current breast-feeding
10. Recreational drug use or excessive alcohol intake
11. Use of drugs known to affect body composition
12. Use of cytotoxic drugs
2. Inability to understand and accept the risks and potential benefits
3. Inability to understand and agree to the compliance requirements of the study
4. Prior gastric surgery including all forms of bariatric surgical or endoscopic procedures
5. A history of previous abdominal surgery which precludes gastric bypass
6. Medical contra-indications to bariatric surgery
7. Dementia, active psychosis, unstable psychiatric disease
8. Concurrent experimental drug use
9. Pregnancy or intending to conceive within 12 months or current breast-feeding
10. Recreational drug use or excessive alcohol intake
11. Use of drugs known to affect body composition
12. Use of cytotoxic drugs
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The N.E.W. Program
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BRIAN B. QUEBBEMANN, M.D., F.A.C.S.
Director
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BRIAN QUEBBEMANN, M.D.
Role: PRINCIPAL_INVESTIGATOR
The N.E.W. Program, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The N.E.W. Program, Inc.
Newport Beach, California, United States
Site Status
Foothill Regional Medical Center
Tustin, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLIMMS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Endoscopic Metabolic and Bariatric Therapies
NCT05725967
ENROLLING_BY_INVITATION
Bariatric Embolization of Arteries for the Treatment of Obesity
NCT02165124
COMPLETED
NA
Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass
NCT00722995
COMPLETED
NA
Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation
NCT02068872
COMPLETED
PHASE1
Comparison of Body Composition Changes With Weight Loss Interventions
NCT07115069
RECRUITING
Autonomic Neural Blockade in Bariatric Surgery
NCT07104825
NOT_YET_RECRUITING
NA
WISE-2B Brain Study (Weight Loss Intervention Surgical Effects on Brain Function)
NCT06861790
RECRUITING
NA
The Effects of Glycemic Optimization Before Gastric Bypass Surgery
NCT01353118
COMPLETED
NA
Effect of Bariatric Surgery Versus Medical Therapy on Metabolic Syndrome
NCT05363059
RECRUITING
Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35
NCT01423877
COMPLETED
Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1
NCT02610530
UNKNOWN
Outcome of Bariatric Surgery in Patients With BMI Greater Than 60 .
NCT04663425
COMPLETED
Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery
NCT06201819
COMPLETED
PHASE4
The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity.
NCT02036138
UNKNOWN
PHASE2/PHASE3
Study of Bariatric Surgery
NCT02857179
RECRUITING
Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes
NCT01278823
COMPLETED
NA
The WISE (Weightloss Intervention Surgical Effects) Brain Study
NCT02137070
COMPLETED
Change in Reward System Activation and Gut Microbiota Following RYGB and Sleeve Gastrectomy for Weight Loss vs. Control-Heads Up Ancillary
NCT02735564
COMPLETED
NA
Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery
NCT02300168
COMPLETED
Effects of Different Surgical Methods to Treat Obesity
NCT01785134
COMPLETED
NA
Laparascopic Sleeve Gastrectomy vs. Endoscopic Gastric Plication in Obesity
NCT05259644
UNKNOWN
NA
Comparative Effectiveness of Metabolic and Bariatric Surgery With PROMs
NCT02749305
COMPLETED
NA
Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus
NCT01083108
TERMINATED
PHASE2
Apnea, Bariatric Surgery Versus Continuous Positive Airway Pressure (CPAP) Trial
NCT01187771
COMPLETED
PHASE2
Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery
NCT01880827
COMPLETED
PHASE1